CY1112679T1 - Κινολινες και θεραπευτικη χρηση αυτων - Google Patents

Κινολινες και θεραπευτικη χρηση αυτων

Info

Publication number
CY1112679T1
CY1112679T1 CY20121100048T CY121100048T CY1112679T1 CY 1112679 T1 CY1112679 T1 CY 1112679T1 CY 20121100048 T CY20121100048 T CY 20121100048T CY 121100048 T CY121100048 T CY 121100048T CY 1112679 T1 CY1112679 T1 CY 1112679T1
Authority
CY
Cyprus
Prior art keywords
hydrogen
halogen
kinolines
therapeutic use
optionally substituted
Prior art date
Application number
CY20121100048T
Other languages
English (en)
Inventor
John Gary Montana
Harry Finch
George Hynd
Michael Colin Cramp
Rosa Arienzo
Neville Mclean
Original Assignee
Pulmagen Therapeutics (Asthma) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706636A external-priority patent/GB0706636D0/en
Priority claimed from GB0724430A external-priority patent/GB0724430D0/en
Application filed by Pulmagen Therapeutics (Asthma) Limited filed Critical Pulmagen Therapeutics (Asthma) Limited
Publication of CY1112679T1 publication Critical patent/CY1112679T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Ενώσεις του τύπου (I) είναι συνδετήρες CRTH2, χρήσιμοι στη θεραπεία, για παράδειγμα, άσθματος και COPD όπου: το R1 είναι αλογόνο ή κύανο, το R2 είναι υδρογόνο ή μεθύλ, τα R3 και R4 ανεξαρτήτως είναι -OR6, C1-C6αλκύλ ή C3-C6κυκλοαλκύλ, με τις τελευταίες δύο ομάδες προαιρετικά να είναι υποκατεστημένες με ένα ή περισσότερα άτομα αλογόνου, το R5 είναι υδρογόνο ή αλογόνο, το R6 είναι C1-C6αλκύλ ή C3-C6κυκλοαλκύλ, εκάτερο των οποίων προαιρετικά είναι υποκατεστημένο με ένα ή περισσότερα άτομα αλογόνου, το Χ είναι -CH2-, -S- ή -Ο-, ένα των Υ και Υ1 είναι υδρογόνο και το άλλο είναι OR6, -C(=O)R7, NR8SO2R6 ή ετεροκυκλική ομάδα επιλεγόμενη από αυτές που αναφέρονται στην προδιαγραφή και τα R6, R7 και R8 είναι όπως ορίζεται στην προδιαγραφή.
CY20121100048T 2007-04-04 2012-01-17 Κινολινες και θεραπευτικη χρηση αυτων CY1112679T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706636A GB0706636D0 (en) 2007-04-04 2007-04-04 Receptor ligands
GB0724430A GB0724430D0 (en) 2007-12-14 2007-12-14 Receptor ligands
EP08736891A EP2139881B1 (en) 2007-04-04 2008-04-03 Quinolines and their therapeutic use

Publications (1)

Publication Number Publication Date
CY1112679T1 true CY1112679T1 (el) 2016-02-10

Family

ID=39561800

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100048T CY1112679T1 (el) 2007-04-04 2012-01-17 Κινολινες και θεραπευτικη χρηση αυτων

Country Status (22)

Country Link
US (2) US8173812B2 (el)
EP (1) EP2139881B1 (el)
JP (1) JP5187862B2 (el)
CN (1) CN101679359B (el)
AT (1) ATE532780T1 (el)
AU (1) AU2008235282B2 (el)
BR (1) BRPI0809983A2 (el)
CA (1) CA2680682C (el)
CY (1) CY1112679T1 (el)
DK (1) DK2139881T3 (el)
EA (1) EA017093B1 (el)
ES (1) ES2375588T3 (el)
HK (1) HK1142604A1 (el)
HR (1) HRP20110987T1 (el)
IL (1) IL201013A (el)
MX (1) MX2009010461A (el)
NZ (1) NZ579659A (el)
PL (1) PL2139881T3 (el)
PT (1) PT2139881E (el)
SI (1) SI2139881T1 (el)
WO (1) WO2008122784A1 (el)
ZA (1) ZA200906384B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375588T3 (es) * 2007-04-04 2012-03-02 Pulmagen Therapeutics (Asthma) Limited Quinolinas y su uso terapéutico.
ATE502920T1 (de) 2007-12-14 2011-04-15 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
CA2805452C (en) * 2010-07-05 2018-07-31 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CN104011021B (zh) 2011-12-21 2016-08-24 埃科特莱茵药品有限公司 杂环衍生物及其作为前列腺素d2受体调节剂的用途
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
TW201416354A (zh) * 2012-07-17 2014-05-01 Boehringer Ingelheim Int 白三烯生成抑制劑
AU2015220750B2 (en) * 2014-02-24 2020-04-16 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
TW297025B (el) * 1992-02-14 1997-02-01 Squibb & Sons Inc
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1928457B1 (en) * 2005-09-30 2012-12-12 Pulmagen Therapeutics (Asthma) Limited Quinolines and their therapeutic use
ES2375588T3 (es) * 2007-04-04 2012-03-02 Pulmagen Therapeutics (Asthma) Limited Quinolinas y su uso terapéutico.

Also Published As

Publication number Publication date
CN101679359B (zh) 2013-03-06
JP5187862B2 (ja) 2013-04-24
CN101679359A (zh) 2010-03-24
HK1142604A1 (en) 2010-12-10
MX2009010461A (es) 2010-02-18
SI2139881T1 (sl) 2012-05-31
EP2139881A1 (en) 2010-01-06
CA2680682C (en) 2015-05-26
AU2008235282A8 (en) 2009-11-26
JP2010523537A (ja) 2010-07-15
ES2375588T3 (es) 2012-03-02
AU2008235282A1 (en) 2008-10-16
PL2139881T3 (pl) 2012-04-30
WO2008122784A1 (en) 2008-10-16
AU2008235282B2 (en) 2011-02-24
CA2680682A1 (en) 2008-10-16
EP2139881B1 (en) 2011-11-09
PT2139881E (pt) 2012-01-17
ZA200906384B (en) 2010-11-24
ATE532780T1 (de) 2011-11-15
HRP20110987T1 (hr) 2012-01-31
BRPI0809983A2 (pt) 2014-10-14
US8173812B2 (en) 2012-05-08
IL201013A (en) 2015-01-29
NZ579659A (en) 2012-01-12
DK2139881T3 (da) 2012-01-30
US20100144787A1 (en) 2010-06-10
US20120184579A1 (en) 2012-07-19
EA017093B1 (ru) 2012-09-28
US8394830B2 (en) 2013-03-12
IL201013A0 (en) 2010-05-17
EA200970911A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
CY1112679T1 (el) Κινολινες και θεραπευτικη χρηση αυτων
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
ATE512954T1 (de) Als inhibitoren des hepatitis-c-virus (hcv) geeignete n-phenyldioxohydropyrimidine
CY1117374T1 (el) Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων
EA201391324A1 (ru) Бис(фторалкил)-1,4-бензодиазепиноновые соединения
EA201290260A1 (ru) Бензимидазол-имидазольные производные
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA201070422A1 (ru) Производные оксадиазола
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
AR072809A1 (es) Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
CO6321159A2 (es) Compuestos pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias